 Denise Damek
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 21 | 2022 | 1145 | 1.790 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 93 | 1.060 |
Why?
| | Glioblastoma | 11 | 2019 | 322 | 1.040 |
Why?
| | Astrocytoma | 5 | 2014 | 115 | 0.990 |
Why?
| | Meningioma | 4 | 2022 | 81 | 0.580 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2022 | 958 | 0.480 |
Why?
| | Chemoradiotherapy | 5 | 2015 | 208 | 0.480 |
Why?
| | Meningeal Carcinomatosis | 2 | 2014 | 8 | 0.440 |
Why?
| | Dacarbazine | 8 | 2016 | 93 | 0.420 |
Why?
| | Radiotherapy, Intensity-Modulated | 4 | 2015 | 129 | 0.390 |
Why?
| | Angiogenesis Inhibitors | 2 | 2014 | 219 | 0.380 |
Why?
| | Glioma | 4 | 2020 | 348 | 0.360 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2012 | 210 | 0.350 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2016 | 67 | 0.340 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.310 |
Why?
| | Quadriplegia | 1 | 2008 | 12 | 0.310 |
Why?
| | Aspergillus | 1 | 2008 | 16 | 0.310 |
Why?
| | Brain Abscess | 1 | 2008 | 10 | 0.310 |
Why?
| | Spinal Cord Diseases | 1 | 2008 | 41 | 0.300 |
Why?
| | Neck | 1 | 2008 | 95 | 0.300 |
Why?
| | Brain Diseases | 1 | 2009 | 136 | 0.290 |
Why?
| | Posture | 1 | 2008 | 175 | 0.280 |
Why?
| | Bevacizumab | 5 | 2020 | 128 | 0.280 |
Why?
| | Range of Motion, Articular | 1 | 2008 | 367 | 0.260 |
Why?
| | Mutation | 3 | 2022 | 3717 | 0.250 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1366 | 0.210 |
Why?
| | Middle Aged | 24 | 2020 | 31136 | 0.200 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 1049 | 0.190 |
Why?
| | Flucytosine | 1 | 2020 | 10 | 0.180 |
Why?
| | Cytosine Deaminase | 1 | 2020 | 15 | 0.180 |
Why?
| | Radiosurgery | 3 | 2010 | 321 | 0.170 |
Why?
| | Seizures | 2 | 2017 | 401 | 0.170 |
Why?
| | Lymphoma | 3 | 2008 | 199 | 0.170 |
Why?
| | Quinazolines | 3 | 2014 | 243 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1560 | 0.160 |
Why?
| | Multiple Sclerosis | 2 | 2012 | 438 | 0.160 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 2046 | 0.150 |
Why?
| | Neurologic Examination | 1 | 2019 | 114 | 0.150 |
Why?
| | Central Nervous System Neoplasms | 3 | 2008 | 148 | 0.150 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 1914 | 0.150 |
Why?
| | Adenocarcinoma | 1 | 2004 | 893 | 0.140 |
Why?
| | Brain | 2 | 2009 | 2673 | 0.140 |
Why?
| | Female | 25 | 2020 | 68734 | 0.140 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2342 | 0.140 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2020 | 52 | 0.140 |
Why?
| | Humans | 33 | 2022 | 129625 | 0.140 |
Why?
| | Magnetic Field Therapy | 1 | 2016 | 3 | 0.130 |
Why?
| | Brain Edema | 2 | 2009 | 60 | 0.130 |
Why?
| | Aged | 18 | 2020 | 22061 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2014 | 757 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 7 | 2016 | 3394 | 0.130 |
Why?
| | Prognosis | 5 | 2015 | 3774 | 0.130 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 168 | 0.120 |
Why?
| | Survival Rate | 4 | 2015 | 1872 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2014 | 208 | 0.120 |
Why?
| | Oligodendroglioma | 1 | 2014 | 15 | 0.120 |
Why?
| | Neoplasms | 1 | 2009 | 2455 | 0.110 |
Why?
| | Combined Modality Therapy | 5 | 2016 | 1203 | 0.110 |
Why?
| | Male | 23 | 2020 | 63670 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2739 | 0.110 |
Why?
| | Adult | 17 | 2017 | 35599 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2016 | 4894 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 1997 | 493 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 212 | 0.100 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2015 | 377 | 0.100 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 388 | 0.090 |
Why?
| | Carcinoma | 1 | 2012 | 214 | 0.090 |
Why?
| | ErbB Receptors | 1 | 2014 | 607 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1035 | 0.080 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2009 | 12 | 0.080 |
Why?
| | Autopsy | 1 | 2009 | 90 | 0.080 |
Why?
| | Chloral Hydrate | 1 | 2008 | 3 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2008 | 23 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2008 | 17 | 0.080 |
Why?
| | Piperidines | 1 | 2010 | 201 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1501 | 0.080 |
Why?
| | Oxycodone | 1 | 2008 | 43 | 0.070 |
Why?
| | Prospective Studies | 7 | 2015 | 7135 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2012 | 507 | 0.070 |
Why?
| | Delirium | 1 | 2009 | 78 | 0.070 |
Why?
| | Drug Combinations | 1 | 2008 | 331 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 95 | 0.070 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 120 | 0.070 |
Why?
| | Hypnotics and Sedatives | 1 | 2008 | 175 | 0.070 |
Why?
| | Antipsychotic Agents | 1 | 2008 | 195 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 325 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2008 | 356 | 0.060 |
Why?
| | Acetaminophen | 1 | 2008 | 247 | 0.060 |
Why?
| | Tumor Burden | 3 | 2012 | 286 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2017 | 2477 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 193 | 0.060 |
Why?
| | Occipital Lobe | 1 | 2004 | 23 | 0.060 |
Why?
| | Young Adult | 4 | 2017 | 12455 | 0.060 |
Why?
| | Drug Overdose | 1 | 2008 | 322 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1432 | 0.060 |
Why?
| | Radiotherapy | 1 | 2004 | 185 | 0.050 |
Why?
| | Time Factors | 3 | 2010 | 6555 | 0.050 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 17 | 0.050 |
Why?
| | Methotrexate | 2 | 2008 | 249 | 0.050 |
Why?
| | Neoplasm Staging | 3 | 2015 | 1282 | 0.050 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2003 | 19 | 0.050 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 35 | 0.050 |
Why?
| | Karnofsky Performance Status | 2 | 2013 | 37 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 33 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2022 | 14522 | 0.050 |
Why?
| | Dementia | 1 | 2005 | 225 | 0.050 |
Why?
| | Quality of Life | 1 | 2013 | 2688 | 0.050 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 767 | 0.050 |
Why?
| | Adolescent | 4 | 2017 | 20412 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2020 | 10219 | 0.050 |
Why?
| | Lomustine | 1 | 2020 | 14 | 0.040 |
Why?
| | Stroke | 1 | 2009 | 1071 | 0.040 |
Why?
| | Survival Analysis | 2 | 2020 | 1269 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 71 | 0.040 |
Why?
| | Radiotherapy Dosage | 2 | 2010 | 251 | 0.040 |
Why?
| | Dexamethasone | 2 | 2012 | 350 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 1999 | 91 | 0.040 |
Why?
| | Reoperation | 2 | 2012 | 541 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1088 | 0.040 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1999 | 78 | 0.040 |
Why?
| | Aged, 80 and over | 5 | 2010 | 7052 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1308 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 611 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 129 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2014 | 1293 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1997 | 334 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2014 | 505 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 209 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1404 | 0.030 |
Why?
| | Acute Disease | 1 | 1997 | 979 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 44 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1017 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2014 | 70 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 202 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2014 | 179 | 0.030 |
Why?
| | Exons | 1 | 2014 | 342 | 0.030 |
Why?
| | Sex Factors | 2 | 2014 | 1970 | 0.020 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2005 | 114 | 0.020 |
Why?
| | Proportional Hazards Models | 2 | 2010 | 1198 | 0.020 |
Why?
| | Chronic Disease | 1 | 1997 | 1720 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2627 | 0.020 |
Why?
| | Age Factors | 2 | 2014 | 3152 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 382 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 161 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 70 | 0.020 |
Why?
| | Carmustine | 1 | 2010 | 50 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 139 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 108 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 1997 | 2720 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 110 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2010 | 121 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3378 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2011 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 232 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 136 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 18 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1616 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 27 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2008 | 80 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 102 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 86 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 482 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 787 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 887 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 819 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3262 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 34 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 164 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 1997 | 5075 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 580 | 0.020 |
Why?
| | Cognition | 1 | 2013 | 1129 | 0.020 |
Why?
| | Dementia, Vascular | 1 | 2005 | 20 | 0.010 |
Why?
| | Pregnancy | 1 | 1997 | 6417 | 0.010 |
Why?
| | Optic Nerve | 1 | 2005 | 64 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2005 | 300 | 0.010 |
Why?
| | Lymphoma, B-Cell | 1 | 2005 | 105 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 858 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2274 | 0.010 |
Why?
| | Astrocytes | 1 | 2005 | 195 | 0.010 |
Why?
| | Microglia | 1 | 2005 | 232 | 0.010 |
Why?
| | Spinal Cord | 1 | 2005 | 353 | 0.010 |
Why?
| | Child | 1 | 2022 | 20884 | 0.010 |
Why?
| | United States | 2 | 2014 | 13871 | 0.010 |
Why?
| | Colorado | 1 | 2010 | 4404 | 0.010 |
Why?
| | Cohort Studies | 1 | 2010 | 5426 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1999 | 26 | 0.010 |
Why?
| | Remission Induction | 1 | 1999 | 274 | 0.010 |
Why?
| | Databases as Topic | 1 | 1998 | 59 | 0.010 |
Why?
| | Forecasting | 1 | 1998 | 361 | 0.010 |
Why?
| | Animals | 1 | 1997 | 35391 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 1998 | 382 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1998 | 1499 | 0.010 |
Why?
| | Hospitals | 1 | 1998 | 637 | 0.010 |
Why?
| | Logistic Models | 1 | 1998 | 1986 | 0.010 |
Why?
| | Registries | 1 | 1998 | 1899 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 5415 | 0.000 |
Why?
| | Risk Factors | 1 | 1998 | 9786 | 0.000 |
Why?
|
|
Damek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|